FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles
Sign Up to like & getrecommendations! Published in 2017 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758834017742576
Abstract: Forkhead box C1 (FOXC1) is an essential member of the forkhead box transcription factors and has been highlighted as an important transcriptional regulator of crucial proteins associated with a wide variety of carcinomas. FOXC1 regulates… read more here.
Keywords: cancer development; foxc1; expression; cancer ... See more keywords
Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s137116
Abstract: and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove… read more here.
Keywords: interactions glimepiride; drug design; drug; design development ... See more keywords
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s194065
Abstract: and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove… read more here.
Keywords: design development; nintedanib severe; drug design; severe idiopathic ... See more keywords
Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12081225
Abstract: Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other… read more here.
Keywords: macrophages glioblastoma; therapy; development therapy; glioblastoma development ... See more keywords